Apixaban with antiplatelet therapy after acute coronary syndrome

John H Alexander; Renato D Lopes; Stefan James; Rakhi Kilaru; Yaohua He; Puneet Mohan; Deepak L Bhatt; Shaun Goodman; Freek W Verheugt; Marcus Flather; Kurt Huber; Danny Liaw; Steen E Husted; Jose Lopez-Sendon; Raffaele De Caterina; Petr Jansky; Harald Darius; Dragos Vinereanu; Jan H Cornel; Frank Cools; Dan Atar; Jose Luis Leiva-Pons; Matyas Keltai; Hisao Ogawa; Prem Pais; Alexander Parkhomenko; Witold Ruzyllo; Rafael Diaz; Harvey White; Mikhail Ruda; Margarida Geraldes; Jack Lawrence; Robert A Harrington; Lars Wallentin; APPRAISE-2 Investigators

doi:10.1056/NEJMoa1105819

Apixaban with antiplatelet therapy after acute coronary syndrome

John H Alexander, Renato D Lopes, Stefan James, Rakhi Kilaru, Yaohua He, Puneet Mohan, Deepak L Bhatt, Shaun Goodman, Freek W Verheugt, Marcus Flather, Kurt Huber, Danny Liaw, Steen E Husted, Jose Lopez-Sendon, Raffaele De Caterina, Petr Jansky, Harald Darius, Dragos Vinereanu, Jan H Cornel, Frank CoolsDan Atar, Jose Luis Leiva-Pons, Matyas Keltai, Hisao Ogawa, Prem Pais, Alexander Parkhomenko, Witold Ruzyllo, Rafael Diaz, Harvey White, Mikhail Ruda, Margarida Geraldes, Jack Lawrence, Robert A Harrington, Lars Wallentin, APPRAISE-2 Investigators

Research output: Contribution to journal › Article › peer-review

952 Citations (Scopus)

Abstract

Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary syndrome.

Original language	English
Pages (from-to)	699-708
Number of pages	10
Journal	New England Journal of Medicine
Volume	365
Issue number	8
DOIs	https://doi.org/10.1056/NEJMoa1105819
Publication status	Published - 25 Aug 2011

Keywords

Acute Coronary Syndrome
Aged
Angina, Unstable
Aspirin
Double-Blind Method
Drug Therapy, Combination
Factor Xa
Female
Hemorrhage
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Myocardial Infarction
Platelet Aggregation Inhibitors
Proportional Hazards Models
Pyrazoles
Pyridones
Stroke
Treatment Outcome

Access to Document

10.1056/NEJMoa1105819

Cite this

Alexander, J. H., Lopes, R. D., James, S., Kilaru, R., He, Y., Mohan, P., Bhatt, D. L., Goodman, S., Verheugt, F. W., Flather, M., Huber, K., Liaw, D., Husted, S. E., Lopez-Sendon, J., De Caterina, R., Jansky, P., Darius, H., Vinereanu, D., Cornel, J. H., ... APPRAISE-2 Investigators (2011). Apixaban with antiplatelet therapy after acute coronary syndrome. New England Journal of Medicine, 365(8), 699-708. https://doi.org/10.1056/NEJMoa1105819

Alexander, John H ; Lopes, Renato D ; James, Stefan ; Kilaru, Rakhi ; He, Yaohua ; Mohan, Puneet ; Bhatt, Deepak L ; Goodman, Shaun ; Verheugt, Freek W ; Flather, Marcus ; Huber, Kurt ; Liaw, Danny ; Husted, Steen E ; Lopez-Sendon, Jose ; De Caterina, Raffaele ; Jansky, Petr ; Darius, Harald ; Vinereanu, Dragos ; Cornel, Jan H ; Cools, Frank ; Atar, Dan ; Leiva-Pons, Jose Luis ; Keltai, Matyas ; Ogawa, Hisao ; Pais, Prem ; Parkhomenko, Alexander ; Ruzyllo, Witold ; Diaz, Rafael ; White, Harvey ; Ruda, Mikhail ; Geraldes, Margarida ; Lawrence, Jack ; Harrington, Robert A ; Wallentin, Lars ; APPRAISE-2 Investigators. / Apixaban with antiplatelet therapy after acute coronary syndrome. In: New England Journal of Medicine. 2011 ; Vol. 365, No. 8. pp. 699-708.

@article{3adea00af67d4d6399c4d522a1b15292,

title = "Apixaban with antiplatelet therapy after acute coronary syndrome",

abstract = "Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary syndrome.",

keywords = "Acute Coronary Syndrome, Aged, Angina, Unstable, Aspirin, Double-Blind Method, Drug Therapy, Combination, Factor Xa, Female, Hemorrhage, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Myocardial Infarction, Platelet Aggregation Inhibitors, Proportional Hazards Models, Pyrazoles, Pyridones, Stroke, Treatment Outcome",

author = "Alexander, {John H} and Lopes, {Renato D} and Stefan James and Rakhi Kilaru and Yaohua He and Puneet Mohan and Bhatt, {Deepak L} and Shaun Goodman and Verheugt, {Freek W} and Marcus Flather and Kurt Huber and Danny Liaw and Husted, {Steen E} and Jose Lopez-Sendon and {De Caterina}, Raffaele and Petr Jansky and Harald Darius and Dragos Vinereanu and Cornel, {Jan H} and Frank Cools and Dan Atar and Leiva-Pons, {Jose Luis} and Matyas Keltai and Hisao Ogawa and Prem Pais and Alexander Parkhomenko and Witold Ruzyllo and Rafael Diaz and Harvey White and Mikhail Ruda and Margarida Geraldes and Jack Lawrence and Harrington, {Robert A} and Lars Wallentin and {APPRAISE-2 Investigators}",

year = "2011",

month = aug,

day = "25",

doi = "10.1056/NEJMoa1105819",

language = "English",

volume = "365",

pages = "699--708",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "8",

}

Alexander, JH, Lopes, RD, James, S, Kilaru, R, He, Y, Mohan, P, Bhatt, DL, Goodman, S, Verheugt, FW, Flather, M, Huber, K, Liaw, D, Husted, SE, Lopez-Sendon, J, De Caterina, R, Jansky, P, Darius, H, Vinereanu, D, Cornel, JH, Cools, F, Atar, D, Leiva-Pons, JL, Keltai, M, Ogawa, H, Pais, P, Parkhomenko, A, Ruzyllo, W, Diaz, R, White, H, Ruda, M, Geraldes, M, Lawrence, J, Harrington, RA, Wallentin, L & APPRAISE-2 Investigators 2011, 'Apixaban with antiplatelet therapy after acute coronary syndrome', New England Journal of Medicine, vol. 365, no. 8, pp. 699-708. https://doi.org/10.1056/NEJMoa1105819

Apixaban with antiplatelet therapy after acute coronary syndrome. / Alexander, John H; Lopes, Renato D; James, Stefan; Kilaru, Rakhi; He, Yaohua; Mohan, Puneet; Bhatt, Deepak L; Goodman, Shaun; Verheugt, Freek W; Flather, Marcus; Huber, Kurt; Liaw, Danny; Husted, Steen E; Lopez-Sendon, Jose; De Caterina, Raffaele; Jansky, Petr; Darius, Harald; Vinereanu, Dragos; Cornel, Jan H; Cools, Frank; Atar, Dan; Leiva-Pons, Jose Luis; Keltai, Matyas; Ogawa, Hisao; Pais, Prem; Parkhomenko, Alexander; Ruzyllo, Witold; Diaz, Rafael; White, Harvey; Ruda, Mikhail; Geraldes, Margarida; Lawrence, Jack; Harrington, Robert A; Wallentin, Lars; APPRAISE-2 Investigators.

In: New England Journal of Medicine, Vol. 365, No. 8, 25.08.2011, p. 699-708.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Apixaban with antiplatelet therapy after acute coronary syndrome

AU - Alexander, John H

AU - Lopes, Renato D

AU - James, Stefan

AU - Kilaru, Rakhi

AU - He, Yaohua

AU - Mohan, Puneet

AU - Bhatt, Deepak L

AU - Goodman, Shaun

AU - Verheugt, Freek W

AU - Flather, Marcus

AU - Huber, Kurt

AU - Liaw, Danny

AU - Husted, Steen E

AU - Lopez-Sendon, Jose

AU - De Caterina, Raffaele

AU - Jansky, Petr

AU - Darius, Harald

AU - Vinereanu, Dragos

AU - Cornel, Jan H

AU - Cools, Frank

AU - Atar, Dan

AU - Leiva-Pons, Jose Luis

AU - Keltai, Matyas

AU - Ogawa, Hisao

AU - Pais, Prem

AU - Parkhomenko, Alexander

AU - Ruzyllo, Witold

AU - Diaz, Rafael

AU - White, Harvey

AU - Ruda, Mikhail

AU - Geraldes, Margarida

AU - Lawrence, Jack

AU - Harrington, Robert A

AU - Wallentin, Lars

AU - APPRAISE-2 Investigators

PY - 2011/8/25

Y1 - 2011/8/25

N2 - Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary syndrome.

AB - Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary syndrome.

KW - Acute Coronary Syndrome

KW - Aged

KW - Angina, Unstable

KW - Aspirin

KW - Double-Blind Method

KW - Drug Therapy, Combination

KW - Factor Xa

KW - Female

KW - Hemorrhage

KW - Humans

KW - Kaplan-Meier Estimate

KW - Male

KW - Middle Aged

KW - Myocardial Infarction

KW - Platelet Aggregation Inhibitors

KW - Proportional Hazards Models

KW - Pyrazoles

KW - Pyridones

KW - Stroke

KW - Treatment Outcome

U2 - 10.1056/NEJMoa1105819

DO - 10.1056/NEJMoa1105819

M3 - Article

C2 - 21780946

VL - 365

SP - 699

EP - 708

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 8

ER -